Back to Search Start Over

International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer

Authors :
Paolo Pedrazzoli
Orazio Caffo
Silvia Novello
Nicolas Dickgreber
E. Stoelben
Alessandra Bearz
Michael Geissler
D. Ladage
G. Valmadre
Monika Serke
G.V. Scagliotti
Gerald Schmid-Bindert
S. Kurz
Frank Griesinger
I. Colantonio
Vanesa Gregorc
G. Borra
Valentina Monica
Gunther H. Wiest
Alessandro Follador
G. Folprecht
Alessandro Morabito
M. Schena
T. Wehler
Christian Grohé
Martin Reck
C. Kropf-Sanchen
C. Cauchi
Valter Torri
Anna Ceribelli
Luca Porcu
Christian Manegold
Antonio Santo
Rita Chiari
Luciana Irtelli
A. Meyer
Publication Year :
2022

Abstract

Background Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) as assessed in resected tumor. Patients and methods Seven hundred and seventy-three completely resected stage II-III NSCLC patients were enrolled and randomly assigned in each of the four genomic subgroups to investigator’s choice of platinum-based chemotherapy (C, n = 389) or tailored chemotherapy (T, n = 384). All anticancer drugs were administered according to standard doses and schedules. Stratification factors included stage and smoking status. The primary endpoint of the study was overall survival (OS). Results Six hundred and ninety patients were included in the primary analysis. At a median follow-up of 45.9 months, 85 (24.6%) and 70 (20.3%) patients died in arms C and T, respectively. Five-year survival for patients in arms C and T was of 65.4% (95% CI (confidence interval): 58.5% to 71.4%) and 72.9% (95% CI: 66.5% to 78.3%), respectively. The estimated hazard ratio (HR) was 0.77 (95% CI: 0.56-1.06, P value: 0.109) for arm T versus arm C. HR for recurrence-free survival was 0.89 (95% CI: 0.69-1.14, P value: 0.341) for arm T versus arm C. Grade 3-5 toxicities were more frequently reported in arm C than in arm T. Conclusion In completely resected stage II-III NSCLC tailoring adjuvant chemotherapy conferred a non-statistically significant trend for OS favoring the T arm. In terms of safety, the T arm was associated with better efficacy/toxicity ratio related to the different therapeutic choices in the experimental arm.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....95484bd5bd48f4904b2d77138f4c9c45